Denali Therapeutics (DNLI) Liabilities and Shareholders Equity (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed 0.42% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $4.6 billion, a 17.3% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 16.69% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.3 billion, up from $1.1 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for DNLI reached as high as $1.6 billion in Q1 2024 and fell as low as $1.1 billion in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $1.3 billion across 5 years, with a median of $1.3 billion in 2022.
• Across the five-year window, Liabilities and Shareholders Equity increased 19.09% in 2024 and slipped 27.4% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then slipped by 20.98% to $1.2 billion in 2023, then gained by 19.09% to $1.4 billion in 2024, then retreated by 16.69% to $1.1 billion in 2025, then grew by 10.58% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.3 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.